Alzheimer’s disease and disseminated mycoses

  • R. Alonso
  • D. Pisa
  • A. Rábano
  • L. Carrasco


Alzheimer’s disease (AD) is characterized by the presence in the brain of amyloid plaques and neurofibrillary tangles that provoke neuronal cell death, vascular dysfunction and inflammatory processes. In the present work, we have analyzed the existence of fungal infection in AD patients. A number of tests have been carried out in blood serum, including the detection of antibodies against several yeast species and fungal proteins, and also the presence of fungal (1,3)-β-glucan. Results from this analysis indicate that there is disseminated fungal infection in the majority of AD patients tested. Of interest, several AD patients contain high levels of fungal polysaccharides in peripheral blood, reflecting that disseminated fungal infection occurs in these patients. Together, these results suggest the presence of disseminated mycoses in blood serum from AD patients. To our knowledge these findings represent the first evidence that fungal infection is detectable in blood samples in AD patients. The possibility that this may represent a risk factor or may contribute to the etiological cause of AD is discussed.


Fungal Infection Blood Serum Brain Bank Fungal Antigen Acute Zonal Occult Outer Retinopathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



We acknowledge an institutional grant to Centro de Biología Molecular from the Fundación Ramón Areces.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer’s disease. Lancet Neurol 368:387–403CrossRefGoogle Scholar
  2. 2.
    Claeysen S, Cochet M, Donneger R, Dumuis A, Bockaert J, Giannoni P (2012) Alzheimer culprits: cellular crossroads and interplay. Cell Signal 24(9):1831–1840PubMedCrossRefGoogle Scholar
  3. 3.
    Mayeux R, Stern Y (2012) Epidemiology of Alzheimer disease. Cold Spring Harb Perspect Med 2(8):a006239Google Scholar
  4. 4.
    Bagger YZ, Tanko LB, Alexandersen P, Qin G, Christiansen C (2004) The implications of body fat mass and fat distribution for cognitive function in elderly women. Obes Res 12(9):1519–1526PubMedCrossRefGoogle Scholar
  5. 5.
    Barberger-Gateau P, Raffaitin C, Letenneur L, Berr C, Tzourio C, Dartigues JF, Alperovitch A (2007) Dietary patterns and risk of dementia: the Three-City cohort study. Neurol 69(20):1921–1930CrossRefGoogle Scholar
  6. 6.
    Shah R (2013) The role of nutrition and diet in Alzheimer disease: a systematic review. J Am Med Dir Assoc 14(6):398–402PubMedCrossRefGoogle Scholar
  7. 7.
    Vignini A, Giulietti A, Nanetti L, Raffaelli F, Giusti L, Mazzanti L, Provinciali L (2013) Alzheimer’s disease and diabetes: new insights and unifying therapies. Curr Diabetes Rev 9(3):218–227PubMedCrossRefGoogle Scholar
  8. 8.
    O’Brien RJ, Wong PC (2011) Amyloid precursor protein processing and Alzheimer’s disease. Annu Rev Neurosci 34:185–204PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Revett TJ, Baker GB, Jhamandas J, Kar S (2012) Glutamate system, amyloid ss peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology. J Psychiatry Neurosci 38(1):6–23CrossRefGoogle Scholar
  10. 10.
    Tanzi RE (2005) The synaptic Abeta hypothesis of Alzheimer disease. Nat Neurosci 8(8):977–979PubMedCrossRefGoogle Scholar
  11. 11.
    Teich A, Arancio O (2012) Is the amyloid hypothesis of Alzheimer’s disease therapeutically relevant? Biochem J 446(2):165–177PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Itzhaki RF, Lin WR, Shang D, Wilcock GK, Faragher B, Jamieson GA (1997) Herpes simplex virus type 1 in brain and risk of Alzheimer’s disease. Lancet 349(9047):241–244PubMedCrossRefGoogle Scholar
  13. 13.
    Itzhaki RF, Wozniak MA, Appelt DM, Balin BJ (2004) Infiltration of the brain by pathogens causes Alzheimer’s disease. Neurobiol Aging 25(5):619–627PubMedCrossRefGoogle Scholar
  14. 14.
    Kountouras J, Tsolaki M, Gavalas E, Boziki M, Zavos C, Karatzoglou P, Chatzopoulos D, Venizelos I (2006) Relationship between helicobacter pylori infection and Alzheimer disease. Neurol 66(6):938–940CrossRefGoogle Scholar
  15. 15.
    Miklossy J, Kis A, Radenovic A, Miller L, Forro L, Martins R, Reiss K, Darbinian N, Darekar P, Mihaly L, Khalili K (2006) Beta-amyloid deposition and Alzheimer’s type changes induced by Borrelia spirochetes. Neurobiol Aging 27(2):228–236PubMedCrossRefGoogle Scholar
  16. 16.
    Urosevic N, Martins RN (2008) Infection and Alzheimer’s disease: the APOE epsilon4 connection and lipid metabolism. J Alzheimers Dis 13(4):421–435PubMedGoogle Scholar
  17. 17.
    Ala TA, Doss RC, Sullivan CJ (2004) Reversible dementia: a case of cryptococcal meningitis masquerading as Alzheimer’s disease. J Alzheimers Dis 6(5):503–508PubMedGoogle Scholar
  18. 18.
    Hoffmann M, Muniz J, Carroll E, De Villasante J (2009) Cryptococcal meningitis misdiagnosed as Alzheimer’s disease: complete neurological and cognitive recovery with treatment. J Alzheimers Dis 16(3):517–520PubMedGoogle Scholar
  19. 19.
    Benito-Leon J, Pisa D, Alonso R, Calleja P, Diaz-Sanchez M, Carrasco L (2010) Association between multiple sclerosis and Candida species: evidence from a case-control study. Eur J Clin Microbiol Infect Dis 29(9):1139–1145PubMedCrossRefGoogle Scholar
  20. 20.
    Carrasco L, Ramos M, Galisteo R, Pisa D, Fresno M, Gonzalez ME (2005) Isolation of Candida famata from a patient with acute zonal occult outer retinopathy. J Clin Microbiol 43(2):635–640PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Pisa D, Alonso R, Carrasco L (2011) Fungal infection in a patient with multiple sclerosis. Eur J Clin Microbiol Infect Dis 30(10):1173–1180PubMedCrossRefGoogle Scholar
  22. 22.
    Pisa D, Alonso R, Jimenez-Jimenez FJ, Carrasco L (2013) Fungal infection in cerebrospinal fluid from some patients with multiple sclerosis. Eur J Clin Microbiol Infect Dis 32(6):795–801PubMedCrossRefGoogle Scholar
  23. 23.
    Pisa D, Ramos M, Garcia P, Escoto R, Barraquer R, Molina S, Carrasco L (2008) Fungal infection in patients with serpiginous choroiditis or acute zonal occult outer retinopathy. J Clin Microbiol 46(1):130–135PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Martinez-Martin P, Avila J (2010) Alzheimer Center Reina Sofia Foundation: fighting the disease and providing overall solutions. J Alzheimers Dis 21(2):337–348PubMedGoogle Scholar
  25. 25.
    Pazos C, Ponton J, Del Palacio A (2005) Contribution of (1->3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 43(1):299–305PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Lamoth F, Cruciani M, Mengoli C, Castagnola E, Lortholary O, Richardson M, Marchetti O (2012) beta-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis 54(5):633–643PubMedCrossRefGoogle Scholar
  27. 27.
    Ostrosky-Zeichner L (2012) Invasive mycoses: diagnostic challenges. Am J Med 125(1 Suppl):S14–S24PubMedCrossRefGoogle Scholar
  28. 28.
    Obayashi T, Yoshida M, Tamura H, Aketagawa J, Tanaka S, Kawai T (1992) Determination of plasma (1→3)-beta-D-glucan: a new diagnostic aid to deep mycosis. J Med Vet Mycol 30(4):275–280PubMedCrossRefGoogle Scholar
  29. 29.
    White PL, Perry MD, Barnes RA (2009) An update on the molecular diagnosis of invasive fungal disease. FEMS Microbiol Lett 296(1):1–10PubMedCrossRefGoogle Scholar
  30. 30.
    Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, Yarasheski KE, Friedrich SW, Demattos RB, May PC, Paul SM, Holtzman DM (2009) A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol 66(1):48–54PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Salloway S, Sperling R, Keren R, Porsteinsson AP, van Dyck CH, Tariot PN, Gilman S, Arnold D, Abushakra S, Hernandez C, Crans G, Liang E, Quinn G, Bairu M, Pastrak A, Cedarbaum JM (2011) A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology 77(13):1253–1262PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Papareddy P, Morgelin M, Walse B, Schmidtchen A, Malmsten M (2012) Antimicrobial activity of peptides derived from human ss-amyloid precursor protein. J Pept Sci 18(3):183–191PubMedCrossRefGoogle Scholar
  33. 33.
    Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B, Burton MA, Goldstein LE, Duong S, Tanzi RE, Moir RD (2010) The Alzheimer’s disease-associated amyloid beta-protein is an antimicrobial peptide. PloS one 5(3):e9505PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Reis HJ, Mukhamedyarov MA, Rizvanov AA, Palotas A (2010) A new story about an old guy: is Alzheimer’s disease infectious? Neurodegener Dis 7(4):272–278PubMedCrossRefGoogle Scholar
  35. 35.
    Butchart J, Holmes C (2012) Systemic and central immunity in Alzheimer’s disease: therapeutic implications. CNS Neurosci Ther 18(1):64–76PubMedCrossRefGoogle Scholar
  36. 36.
    Goldgaber D, Harris HW, Hla T, Maciag T, Donnelly RJ, Jacobsen JS, Vitek MP, Gajdusek DC (1989) Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci USA 86(19):7606–7610PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Sutinen EM, Pirttila T, Anderson G, Salminen A, Ojala JO (2012) Pro-inflammatory interleukin-18 increases Alzheimer’s disease-associated amyloid-beta production in human neuron-like cells. J Neuroinflammation 9:199PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Wuthrich M, Deepe GS Jr, Klein B (2012) Adaptive immunity to fungi. Annu Rev Immunol 30:115–148PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Borenstein AR, Wu Y, Mortimer JA, Schellenberg GD, McCormick WC, Bowen JD, McCurry S, Larson EB (2005) Developmental and vascular risk factors for Alzheimer’s disease. Neurobiol Aging 26(3):325–334PubMedCrossRefGoogle Scholar
  40. 40.
    Deramecourt V, Slade JY, Oakley AE, Perry RH, Ince PG, Maurage CA, Kalaria RN (2012) Staging and natural history of cerebrovascular pathology in dementia. Neurology 78(14):1043–1050PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, Petersen RC, Schneider JA, Tzourio C, Arnett DK, Bennett DA, Chui HC, Higashida RT, Lindquist R, Nilsson PM, Roman GC, Sellke FW, Seshadri S (2011) Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42(9):2672–2713PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Kalaria R (2002) Similarities between Alzheimer’s disease and vascular dementia. J Neurol Sci 203:29–34PubMedCrossRefGoogle Scholar
  43. 43.
    Kalaria R, Akinyemi R, Ihara M (2012) Does vascular pathology contribute to Alzheimer changes? J Neurol Sci 322(1–2):141–147PubMedCrossRefGoogle Scholar
  44. 44.
    Liu CC, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9(2):106–118PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Centro de Biología Molecular Severo Ochoa CSIC-UAMUniversidad Autónoma de MadridMadridSpain
  2. 2.Department of Neuropathology and Tissue Bank, Unidad de Investigación Proyecto Alzheimer, Fundación CIENInstituto de Salud Carlos IIIMadridSpain

Personalised recommendations